Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: tonyt who wrote (27960)	2/7/1999 12:12:00 PM
From: Machaon	Read Replies (1) \| Respond to of 32384

"We are on track to strengthen our position in CTCL by submitting New Drug Applications to the FDA for Targretin(R) capsules (bexarotene) and Targretin(R) gel (bexarotene) 1.0% in 1999." Looks like Ligand is going to be very busy in 1999. Since you seem so very interested in LGND, a stock that you don't understand, are you a buyer of LGND or are you going to play it short? Instead of you posting thousands of posts about LGND's price and movement, after it happens, how about commenting on Ligand's attack against CTCL. There are only 1000 new cases of CTCL per year. Why in the world would Ligand attack such a small population? << I see you're back to your old ways of attacking people with insults. >> Only a selected few who deserve it! <g>